{"id":"NCT00160615","sponsor":"UCB Japan Co. Ltd.","briefTitle":"Follow-up Study of L059 (Levetiracetam) in Epileptic Patients With Partial Onset Seizures by Open Label Method","officialTitle":"Follow-up Study of L059 (Levetiracetam) in Epileptic Patients With Partial Onset Seizures by Open Label Method","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2001-09-12","primaryCompletion":"2007-01-17","completion":"2007-01-17","firstPosted":"2005-09-12","resultsPosted":"2019-06-10","lastUpdate":"2019-06-10"},"enrollment":154,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Epilepsy, Partial"],"interventions":[{"type":"DRUG","name":"Levetiracetam","otherNames":["Keppra"]}],"arms":[{"label":"Levetiracetam","type":"EXPERIMENTAL"}],"summary":"The safety and efficacy of L059 was evaluated in patients who completed \"N165 Clinical Trial of L059\". They received L059 at a daily dose from 1,000 mg to 3,000 mg in addition to their standard concomitant AEDs","primaryOutcome":{"measure":"Partial (Type I) Seizure Frequency Per Week by Analysis Visit","timeFrame":"From Baseline up to 54 months","effectByArm":[{"arm":"N165 Randomized Treatment PBO","deltaMin":1.68,"sd":null},{"arm":"N165 Randomized Treatment LEV","deltaMin":2.19,"sd":null}],"pValues":[]},"eligibility":{"minAge":"16 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":3},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":[],"seeAlso":["http://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm"]},"adverseEventsSummary":{"seriousAny":{"events":12,"n":50},"commonTop":["Nasopharyngitis","Contusion","Headache","Somnolence","Upper respiratory tract inflammation"]}}